Diltiazem Hydrochloride

證據等級: L5

預測適應症: 0 個

Diltiazem Hydrochloride: Repurposing Evaluation — Insufficient Data for Full Analysis

One-Sentence Summary

Diltiazem Hydrochloride is a widely used cardiovascular agent, but the current Evidence Pack contains neither original indication records nor TxGNN-predicted new indications for this compound. Without prediction outputs or supporting evidence, a complete drug repurposing evaluation cannot be produced at this stage — a data remediation step is required before proceeding.

Quick Overview

Item	Content
Original Indication	Not available in current dataset
Predicted New Indication	Not available — TxGNN output not retrieved
TxGNN Prediction Score	Not available
Evidence Level	Cannot be determined
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why a Full Analysis Cannot Be Completed

The Evidence Pack for Diltiazem Hydrochloride is missing three critical inputs that the standard repurposing workflow requires:

No TxGNN predicted indications. The predicted_indications array is empty, meaning the TxGNN model either was not run for this compound or its output was not captured in this Evidence Pack. Without a predicted indication, there is no repurposing hypothesis to evaluate, no mechanistic link to assess, and no evidence to tabulate.

No original indication or MOA data. The original_indications list is empty and mechanism of action is recorded as unavailable. The query log confirms DrugBank was queried on 2026-03-29 and returned one result — this data exists but was not parsed into the Evidence Pack. Similarly, the package insert query returned one result on the same date but was also not incorporated.

No safety information. Warnings and contraindications are absent. The drug–drug interaction query returned no results.

New Zealand Market Information

Diltiazem Hydrochloride currently has zero registered authorizations in New Zealand based on data retrieved on 2026-03-29. No product names, dosage forms, or approved indications are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is structurally incomplete — no TxGNN predictions, no indication data, no MOA, and no safety records were incorporated, making it impossible to evaluate any repurposing candidate or assign an evidence level.

To proceed, the following is needed:

Run TxGNN prediction for DILTIAZEM HYDROCHLORIDE and populate predicted_indications before re-generating this report
Parse the DrugBank result already retrieved on 2026-03-29 (query log ID 3, result count = 1) — extract MOA, categories, and toxicity fields and add to Evidence Pack
Parse the package insert already retrieved on 2026-03-29 (query log ID 4, result count = 1) — extract original indications, warnings, and contraindications
Re-query market registration in New Zealand (Medsafe) if a different registry is intended, as the TFDA query returned 0 results
Re-generate this Evidence Pack once the four items above are resolved, then re-run report generation

Note: The query log indicates that DrugBank and package insert sources both returned data — the bottleneck is parsing, not data availability. Resolving the parsing step may resolve most of the current data gaps without additional external queries.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.